The role of chemotherapy in patients with established gastric cancer.

Details

Serval ID
serval:BIB_6D5F8B57D8F5
Type
Article: article from journal or magazin.
Collection
Publications
Title
The role of chemotherapy in patients with established gastric cancer.
Journal
Best Practice and Research. Clinical Gastroenterology
Author(s)
Wagner A.D., Schneider P.M., Fleig W.E.
ISSN
1521-6918 (Print)
ISSN-L
1521-6918
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
20
Number
4
Pages
789-799
Language
english
Abstract
Chemotherapy significantly improves survival in comparison to best supportive care in patients with metastasised gastric cancer. In patients for whom a three-drug-combination is considered as the treatment of choice, ECF (epirubicin, cisplatin and 5-FU as a continuous infusion) should be regarded as standard of care. However, results for ECF have been challenged by the recently presented REAL-2-trial, which demonstrated a significant survival benefit for EOX (epirubicin, oxaliplatin, capecitabine) over ECF. Adjuvant 5-FU-based chemoradiation should be discussed in patients with inadequate lymphadenectomy, but is not internationally accepted as standard of care: whether patients with adequate lymhphadenectomy benefit from adjuvant chemoradiotherapy is currently unclear. According to the results of the UK MAGIC trial, perioperative treatment with ECF (3 cycles prior to and post surgery) results in a significantly reduced risk of death for patients with resectable gastric cancer as compared to surgery alone. Neo-adjuvant chemotherapy has the ability to downsize gastric tumours and appears to improve R0-resection rates, but its potential to improve overall survival is still unclear.
Keywords
Antineoplastic Agents/therapeutic use, Humans, Neoplasm Staging, Stomach Neoplasms/drug therapy, Stomach Neoplasms/pathology, Treatment Outcome
Pubmed
Web of science
Create date
02/02/2016 17:40
Last modification date
20/08/2019 14:27
Usage data